• Home
  • NEW DAY MEDICINE
  • 4 (90) 2026
  • 39 -4 (90) 2026 - Isroilov I.I., Ismatova M.N. - IDENTIFICATION OF DIAGNOSTIC MARKERS OF CHRONIC RENAL FAILURE IN THE BACKGROUND OF METABOLIC SYNDROME

39 -4 (90) 2026 - Isroilov I.I., Ismatova M.N. - IDENTIFICATION OF DIAGNOSTIC MARKERS OF CHRONIC RENAL FAILURE IN THE BACKGROUND OF METABOLIC SYNDROME

IDENTIFICATION OF DIAGNOSTIC MARKERS OF CHRONIC RENAL FAILURE IN THE BACKGROUND OF METABOLIC SYNDROME

Isroilov I.I. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Ismatova M.N. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

This article presents the results of identifying diagnostic markers for the development of chronic renal failure (CRF) in the background of metabolic syndrome (MS). The study involved 120 subjects: 45 patients with MS and CRF (group 1), 40 patients with MS only (group 2), and 35 healthy individuals (group 3). The results showed that in MS and CRF comorbidity, glomerular filtration rate was significantly decreased (52.4±8.7 ml/min), while microalbuminuria (86.7±12.5 mg/l) and cystatin-C (1.84±0.32 mg/l) were significantly higher compared to the control group (p<0.05). ROC analysis demonstrated that cystatin-C had the highest diagnostic value (AUC=0.91). The developed diagnostic algorithm enables early detection of CRF in MS patients.

Keywords: metabolic syndrome, chronic renal failure, cystatin-C, microalbuminuria, glomerular filtration rate, diagnostic markers.

First page

289

Last page

292

For citation:Isroilov I.I., Ismatova M.N. - IDENTIFICATION OF DIAGNOSTIC MARKERS OF CHRONIC RENAL FAILURE IN THE BACKGROUND OF METABOLIC SYNDROME//New Day in Medicine 4(90)2026 289-292 https://newdayworldmedicine.com/en/new_day_medicine/4-90-2026

List of References

  1. World Health Organization. Global report on diabetes. Geneva: WHO; 2016. 88 p.
  2. Alberti KGMM, Zimmet P, Shaw J. The metabolic syndrome – a new worldwide definition. Lancet. 2005;366:1059–1062. doi:10.1016/S0140-6736(05)67402-8
  3. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140:167–174. doi:10.7326/0003-4819-140-3-200402030-00007
  4. Thomas G, Sehgal AR, Kashyap SR, et al. Metabolic syndrome and kidney disease: a systematic review. Clin J Am Soc Nephrol. 2011;6:2364–2373. doi:10.2215/CJN.02180311
  5. Zokirov VZ. Chronic liver disease and COVID-2019 (literature review and own data). Research Journal of Trauma and Disability Studies. 2022;1(4):24–29.
  6. Zokirov VZ. Comparative analysis of the results of laboratory-biochemical analysis in middle-aged and elderly patients with non-alcoholic fatty liver disease after COVID-19. Art of Medicine. International Medical Scientific Journal. 2022;2(1).
  7. Zokirov VZ. COVID-19 o’tkazgan va o’tkazmagan jigarning noalkagol yog’ xastaligi bilan og’rigan bemorlar klinikasi va laborator tahlillarining solishtirma tahlili. Scientific Progress. 2022;3(1):670–675.
  8. Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012;379:165–180. doi:10.1016/S0140-6736(11)60178-5
  9. Devarajan P. Biomarkers for the early detection of acute and chronic kidney injury. Curr Opin Nephrol Hypertens. 2010;19:553–558. doi:10.1097/MNH.0b013e32833d5e14
  10. Stevens PE, Levin A. Evaluation and management of CKD. Kidney Int Suppl. 2013;3:1–150. doi:10.1038/kisup.2012.73

    file

    download